Three independent discounted-cash-flow-style models value Coherus Oncology, Inc. Common Stock every trading day. 0 of 3 currently price CHRS above its market price.
| Free Cash Flow model | $-1.05 |
| Excess Profit model | $-0.97 |
| Residual Earnings model | $-0.02 |
| Dividend Discount model | — |
| Piotroski F-Score | 5 / 9 |
| Return on invested capital | +142.4% |
| Net debt / EBITDA | — |
| Gross margin | +67.2% |
| Revenue CAGR | -41.5% |
| Cash conversion | -0.8× |
| Dividend yield | — |
| Buyback yield | -2.3% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open CHRS in StockKitty